



The ACME Laboratories Ltd.

MANUFACTURERS OF ETHICAL DRUGS & MEDICINES

ISO 9001:2008 CERTIFIED COMPANY


O/C

Ref. No. ACME /CA/CS/0595/2016

14 August 2016

The Chairman-

Bangladesh Securities and Exchange Commission
Jibon Bima Tower (15th, 16th & 20th Floor)
10, Dilkusha Commercial Area
Dhaka-1000



Kind Attention: Mr. Kamrul Anam Khan, Director

Subject: Audited Status Report on utilization of Initial Public Offering proceeds of The ACME Laboratories Ltd.

Dear Sir,

In compliance with the clause 3 & 4 of Part-C of the Letter of Consent vide no. BSEC/CI/BB-03/2014/143; dated: 15 March 2016 accorded by your esteemed organization, we are pleased to enclose herewith the Audited Status Report on utilization of Initial Public Offering proceeds of The ACME Laboratories Ltd. duly authenticated by the Board of Directors in its 62nd Meeting held on 11 August 2016 for your kind perusal and record please.

Thanking you and assuring of our best attention for all the time to come.


(Mizanur Rahman Sinha)
Managing Director



Enclosure: As stated above

Copy to:

01. The Managing Director, Dhaka Stock Exchange Limited
02. The Managing Director, Chittagong Stock Exchange Limited
03. The Chief Executive Officer, ICB Capital Management Limited

Corporate Office:

Court de la ACME


1/4, Kallayanpur, Mirpur Road
Dhaka-1207, Bangladesh.
Phone: +88-02-9004194-6
Fax: +88-02-9016872

www.acmeglobal.com

Plant:

Dhamrai, Dhaka, Bangladesh
Phone: +88-02-7730881-2
88-02-7730816-7, 7730142
Fax: +88-02-7730141

Auditors' Report



Name of Client

The ACME Laboratories Ltd.
Utilization of IPO Proceeds
for the month ended July 31, 2016

পিনাকী এণ্ড কোম্পানী Pinaki & Company

AHSANDELL, 2/A, Mymensingh Road (2nd Floor), Shahbag, Dhaka-1000, Bangladesh
Tel # 966-0944, 966-5095, Fax # 88-02-9672726
E-mail : pinaki_co@yahoo.com
GAUSIA BHABAN (4th Floor), 156, Agrabad C/A, Chittagong.
Tel # 031-710451, Mob # 01711-830577, 01914-313641



AUDITORS' REPORT
on
Utilization of IPO Proceeds

We have audited the annexed Statement of Initial Public Offering (IPO) Proceeds Utilization of The ACME Laboratories Ltd. for the month ended July 31, 2016.

Management's Responsibility for the IPO proceeds Utilization

Management is responsible for the preparation and fair presentation of these IPO proceeds utilization statement in accordance with Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 and other applicable laws and regulations.

Auditor's Responsibility

Our responsibility is to express an independent opinion on these Initial Public Offering (IPO) proceeds utilization statement based on our audit. We conducted our audit in accordance with Bangladesh Standards on Auditing (BSA), Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 and other applicable laws and regulations.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our Opinion, the Statement of Initial Public Offering (IPO) Proceeds Utilization, Prepared in accordance with Bangladesh Securities and Exchange Commission Rules 1987 and Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 gives a true and fair view of the statement for the month ended July 31, 2016 and comply with the prospectus.

As per TOR, We draw attention to the following matter:

1. The Company has utilized cumulative amounting Tk. 22,834,710 up to 31 July 2016 of which amounting Tk. 8,059,147 is for the month of July 2016 in respect of Construction of Steroid and Hormone project.
2. The Company also utilized amounting Tk. 28,318,000 up to 31 July 2016 as IPO expenses of which Tk. 7,668,000 is for the month of July 2016 from IPO proceeds fund.

We also state that:

- a) IPO proceeds have been utilized for the purposes as specified in the prospectus;
- b) IPO proceeds have been utilized in line with the conditions of the BSEC's consent letter for the IPO;
- c) Utilization of IPO proceeds is being under completion within the time frame as specified in the prospectus;
- d) Utilization of IPO proceeds is accurate for the purpose of the company as mentioned in the prospectus;
- e) Audit statement has been made on verification of all necessary documents/papers/vouchers in support of utilization of IPO proceeds making reconciliation with bank statements.

Date : 11 August 2016
Dhaka.

Pinaki & Co 11.8.16
Pinaki & Company
Chartered Accountants

পিনাকী এণ্ড কোম্পানী

Pinaki & Company

Chartered Accountants



The ACME Laboratories Ltd. Statement of Utilization of IPO Proceeds For the month ended 31 July 2016

For the month ended 31 July 2015											
Sl No.	Projects	Estimated cost for Project Implementation as per Prospectus		Estimated Time for completion as per Prospectus	Investment/Expenses so far made (up to 31 July 2016)				Investment/Expenses Yet to be made		Remarks
		Cost Breakdown	Amount		Upto previous Month	Amount During the Month	Upto this Month	%	Amount	%	
1	Steroid and Hormone	Civil Construction	335,800,000	Within 2 years of receive IPO fund	14,775,563.00	8,059,147	6.80%	22,834,710	312,965,290	93.20%	
		Machinery & Equipment	598,600,000		-	-	-	598,600,000	100%		
		Utility	339,600,000		-	-	-	339,600,000	100%		
		Warehouse	39,500,000		-	-	-	39,500,000	100%		
		Vehicle	5,000,000		-	-	-	5,000,000	100%		
		Consultancy fee	26,300,000		-	-	-	26,300,000	100%		
		Contingencies	13,200,000		-	-	-	13,200,000	100%		
		Sub Total	1,358,000,000		14,775,563.00	8,059,147	1.68%	22,834,710	1,335,165,290	98.32%	
2	Oncology	Civil Construction	335,800,000	Within 2.5 years of receive IPO fund	-	-	-	-	367,000,000	100%	
		Machinery & Equipment	367,000,000		-	-	-	350,000,000	100%		
		Utility	350,000,000		-	-	-	50,000,000	100%		
		Warehouse	50,000,000		-	-	-	5,000,000	100%		
		Vehicle	5,000,000		-	-	-	22,100,000	100%		
		Consultancy fee	22,100,000		-	-	-	11,100,000	100%		
		Contingencies	11,100,000		-	-	-	1,141,000,000	100%		
		Sub Total	1,141,000,000		-	-	-	417,500,000	100%		
3	Ayurvedic, Modern Herbal and Neutraceuticals	Civil Construction	417,500,000	Within 2.5 years of receive IPO fund	-	-	-	-	857,200,000	100%	
		Machinery & Equipment	857,200,000		-	-	-	404,000,000	100%		
		Utility	404,000,000		-	-	-	11,000,000	100%		
		Warehouse	11,000,000		-	-	-	5,000,000	100%		
		Vehicle	5,000,000		-	-	-	33,900,000	100%		
		Consultancy fee	33,900,000		-	-	-	16,900,000	100%		
		Contingencies	16,900,000		-	-	-	1,745,500,000	100%		
		Sub Total	1,745,500,000		-	-	-	28,318,000	39,982,000	59%	
4	IPO Expenses		68,300,000	N/A	20,650,000	7,668,000	41.46%	51,152,710	4,261,647,290	98.81%	
	Grand Total		4,312,800,000		35,425,563	15,727,147	1.19%				

Amin

(Afzalur Rahman Sinha)
Chairman

Mizanur Rahman Sinha

(Mizanur Rahman Sinha)
Managing Director

Fouja Haque, FCA

(Fouja Haque, FCA)
Independent Director & Chairman of the Audit Committee

The ACME Laboratories Ltd.

Reconciliation Statement of IPO Proceeds
For the Month Ended 31 July 2016

Cash at Bank as at 31 July 2016

Standard Chartered Bank Bangladesh, ESCREW A/C No: 02-1111195-03

Workings-1 14,236,948.68

Standard Chartered Bank Bangladesh, SND A/C No: 02-1111195-01

Workings-2 545,965,305.32

Workings-1

Standard Chartered Bank Bangladesh, ESCREW A/C No: 02111119503

Particulars	Amount in BDT
Opening Balance as per Bank Statement as at 01 July 2016	11,425,693.67
Add : Received for the purpose of	17,088,728.40
-Interest Income	15,819,207.64
- Reversal of AIT against Interest Income due to wrong calculation by Bank	1,269,520.76
Less: Payment for the Purpose of	14,277,473.39
- Reversal of Interest Income due to wrong calculation of Bank	12,695,207.63
-AIT on Interest Income	1,581,920.76
-Bank Charge & VAT	345.00
Closing Balance as per Bank Statement as at 31 July 2016	14,236,948.68

Workings-2

Standard Chartered Bank Bangladesh, SND A/C No: 02-1111195-01

Particulars	Amount in BDT
Opening Balance as per Bank Statement as at 01 July 2016	559,587,950.11
Add : Received for the purpose of	2,339,902.00
-Interest Income	2,337,820.53
- Reversal of Bank charge	2,081.47
Less: Payment for the Purpose of	15,962,546.79
-Construction of Steroid and Hormone Project	8,059,147.29
-IPO Expenses	7,668,000.00
-AIT on Interest Income	233,782.05
-Bank Charge	1,617.45
Closing Balance as per Bank Statement as at 31 July 2016	545,965,305.32


(Fouzia Haque, FCA)

Independent Director &
Chairman of the Audit Committee


(Mizanur Rahman Sinha)

Managing Director



(Afzalur Rahman Sinha)
Chairman


Pinaki & Company
Chartered Accountants